Categories: HealthcareNews

RazorMetrics Launches Polypharmacy Solution to Reduce Cost and Medication Burden that Affects 24% of US Working Population

AI-driven approach targets medication overload with precision tools, optimizing safety and reducing costs

AUSTIN, Texas, Jan. 13, 2025 /PRNewswire/ — RazorMetrics, a leading innovator in pharmacy technology solutions, today announced the launch of its Polypharmacy Solution, designed to tackle the growing challenges of medication overload and rising prescription drug costs. Built on proprietary technology and patent-pending algorithms, this solution provides a physician-focused approach to managing polypharmacy, defined as the use of five or more prescription medications per month.

“Polypharmacy is a critical issue impacting millions of Americans,” said Tom Dorsett, CEO at RazorMetrics. “Physicians often lack a complete view of their patient’s medication history due to fragmented electronic health records across networks. Our solution bridges this gap by analyzing client data and identifying polypharmacy cohorts, equipping physicians with the insights they need to reduce risks.”

With 24% of adults aged 40–79 taking five or more prescriptions monthly, polypharmacy presents serious risks, including drug-to-drug interactions, poor adherence, and increased healthcare costs.

By directly engaging physicians within their existing workflows, RazorMetrics identifies potentially unnecessary or conflicting prescriptions, prompting a review to ensure medications are necessary, correctly dosed, and free from harmful interactions. This process not only enhances patient safety but also generates substantial savings for healthcare plans, employers, and members.

Proven Results

As an example, in its initial cohort of clients over a 12-month period, RazorMetrics’ Polypharmacy Solution delivered significant results. Highlights include:

  • Clients saved an additional 54% on top of RazorMetrics’ RxEdge solution.

  • Members saved an extra 31% by lowering copays and avoiding unnecessary prescriptions.
  • Tens of thousands of deprescribed medications, reducing risks of adverse effects and improving adherence.

Statistical analysis confirms the solution’s effectiveness, showing a marked increase in deprescriptions post-intervention. Physicians reported greater visibility into patients’ full medication histories, overcoming challenges posed by fragmented electronic health record systems.

“The results we’ve achieved in just the first 12 months are a testament to the transformative power of our Polypharmacy Solution,” continued Dorsett. “Unlike solutions that burden members, our approach engages physicians—the most qualified stakeholders—to address polypharmacy, delivering better patient outcomes and substantial savings for healthcare organizations.”

The RazorMetrics Polypharmacy Solution is available now and can be implemented at any time during the plan year. To learn more or schedule a demo, visit razormetrics.com.

About RazorMetrics
RazorMetrics creates cutting-edge pharmacy cost containment solutions to quickly and easily reduce drug costs. Its proprietary technology automatically initiates cost-saving opportunities through medication switching, deprescription, deduplication, and more–all while adapting to fit client’s plan, preferences, and formulary. RazorMetrics conveniently plugs into prescriber’s existing workflow, improving healthcare decisions while seamlessly reducing medication costs for members and plan sponsors. Based in Austin, TX, RazorMetrics supports self-funded employers, health plans, PBMs, and organizations to bring clarity, efficiency, and more value to their pharmacy benefits.

Media Contact
Carson Jones
512.663.3703
carson.jones@anthonybarnum.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/razormetrics-launches-polypharmacy-solution-to-reduce-cost-and-medication-burden-that-affects-24-of-us-working-population-302348394.html

SOURCE RazorMetrics

Staff

Recent Posts

CannaPharmaRX Provides Corporate Update and Outlines Growth Strategy for 2026

CALGARY, AB / ACCESS Newswire / January 12, 2026 / CannaPharmaRX, Inc. (OTC PINK:CPMD), an…

11 hours ago

TempraMed Closes C$2.5 Million Fully Subscribed Private Placement

Vancouver, British Columbia--(Newsfile Corp. - January 12, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE:…

14 hours ago

TruuCONNECT NJ Statewide Digital Hub Empowers Users to Find Verified, Local Community Resources and Support – Anonymously and in Real Time

MOUNT LAUREL, N.J., Jan. 12, 2026 /PRNewswire/ -- Born out of a partnership between the…

14 hours ago

Nuvo Unveils Large-Scale AI-Ready Pregnancy Dataset Built on Real-World Maternal and Fetal Physiology

Unique longitudinal dataset combining native fetal and maternal ECG with phonocardiography supports deeper insights into…

14 hours ago

Alamar Biosciences Announces Launch of NULISAqpcr™ AD 5-plex Assay, Advancing Blood Based Biomarker Detection in Alzheimer’s Disease Research

FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision…

14 hours ago

RxAnte Announces Strategic Growth Investment from Primus Capital

PORTLAND, Maine, Jan. 12, 2026 /PRNewswire/ -- RxAnte, the leading provider of analytics, software, and…

14 hours ago